middl
east
respiratori
syndrom
coronaviru
merscov
recent
emerg
caus
agent
sever
respiratori
diseas
human
construct
recombin
modifi
vaccinia
viru
ankara
mva
express
fulllength
merscov
spike
protein
mvamerss
genet
stabil
growth
characterist
mvamerss
make
suitabl
candid
vaccin
clinic
test
vaccin
mice
produc
high
level
serum
antibodi
neutral
merscov
thu
mvamerss
may
serv
develop
emerg
vaccin
merscov
iddl
east
respiratori
syndrom
coronaviru
merscov
novel
infecti
agent
caus
sever
respiratori
diseas
death
human
first
describ
date
total
case
infect
merscov
confirm
includ
death
http
infect
geograph
link
middl
east
ie
jordan
saudi
arabia
qatar
unit
arab
emir
case
also
occur
unit
kingdom
germani
franc
itali
epidemiolog
merscov
infect
remain
unclear
viru
suspect
persist
anim
reservoir
caus
zoonot
infect
human
merscov
spike
protein
characterist
structur
compon
virion
membran
form
larg
protrud
spike
surfac
viru
domain
mediat
bind
dipeptidyl
peptidas
serv
host
cell
receptor
merscov
importantli
protein
consid
key
compon
vaccin
coronaviru
infect
includ
sever
acut
respiratori
syndrom
sar
modifi
vaccinia
viru
ankara
mva
highli
attenu
strain
vaccinia
viru
origin
growth
select
chicken
embryo
fibroblast
cef
show
characterist
replic
defect
mammalian
cell
present
mva
serv
one
advanc
recombin
poxviru
vector
preclin
research
human
clinic
trial
develop
new
vaccin
infecti
diseas
cancer
show
fulllength
protein
merscov
express
mva
produc
nglycosyl
protein
specif
recogn
antibodi
western
blot
analysi
studi
suggest
cleavag
matur
fulllength
glycoprotein
aminotermin
domain
carboxytermin
domain
put
anchor
membran
test
vaccin
mice
recombin
mva
express
protein
induc
high
level
circul
antibodi
neutral
merscov
tissu
cultur
infect
construct
character
recombin
mva
cdna
contain
entir
gene
sequenc
encod
merscov
genbank
access
obtain
dna
synthesi
invitrogen
life
technolog
regensburg
germani
modifi
introduc
silent
mutat
remov
three
termin
signal
tttttnt
vaccinia
viru
transcript
merss
furthermor
gener
second
version
contain
tag
sequenc
encod
nine
amino
acid
ypydvpdya
influenza
viru
hemagglutinin
ha
tag
attach
c
terminu
merss
ha
merss
merss
ha
clone
transcript
control
vaccinia
viru
earlyl
promot
introduc
homolog
recombin
exist
delet
site
delet
iii
mva
genom
fig
mva
express
merss
merss
ha
mvamerss
mvamerss
ha
respect
obtain
use
standard
method
gener
recombin
mva
vaccin
suitabl
clinic
test
describ
previous
briefli
transient
coproduct
fluoresc
marker
protein
mcherri
control
vaccinia
viru
late
promot
use
isol
clonal
recombin
virus
screen
fluoresc
cell
foci
repetit
plaqu
purif
stage
immunostain
infect
cell
cultur
antiha
tag
monoclon
polyclon
antibodi
merscovinfect
macaqu
suggest
synthesi
recombin
ha
protein
cef
vero
cell
atcc
molecular
mass
polypeptid
detect
sdspage
significantli
higher
kda
predict
merscov
protein
base
nucleotid
sequenc
netnglyc
server
analysi
suggest
least
like
nglycosyl
site
asnx
serthr
coand
posttransl
modif
therefor
investig
glycosyl
pattern
express
ha
protein
use
treatment
peptidenglycosidas
f
pngase
f
endoglycosidas
h
endo
h
new
england
biolab
follow
western
blot
fig
ha
produc
mvamerss
ha
infect
vero
cell
treat
pngase
f
remov
nlink
oligosaccharid
chain
glycoprotein
treatment
reduc
protein
doublet
sharp
protein
band
kda
valu
close
match
predict
mass
unmodifi
merscov
protein
similarli
pngase
f
treatment
convert
protein
fragment
polypeptid
molecular
mass
kda
endo
h
cleav
nlink
highmannos
oligosaccharid
synthes
endoplasm
reticulum
matur
complex
oligosaccharid
golgi
apparatu
western
blot
analysi
ha
digest
endo
h
reveal
band
protein
indic
complet
hydrolysi
nlink
oligosaccharid
addit
subpopul
ha
migrat
origin
size
kda
indic
resist
endo
h
treatment
note
protein
subpopul
remain
larg
unaffect
endo
h
digest
immunogen
mvamerss
mice
balbc
mice
vaccin
intramuscularli
pfu
mvamerss
week
twenti
day
first
immun
day
second
immun
serum
sampl
test
capac
neutral
merscov
emc
isol
tissu
cultur
infect
use
tissu
cultur
infect
dose
tcid
vero
cell
tcid
cell
even
singl
applic
mvamerss
induc
low
level
virusneutr
antibodi
eight
anim
test
fig
booster
immun
vaccin
anim
produc
high
level
circul
antibodi
neutral
merscov
fig
c
contrast
neutral
antibodi
detect
serum
sampl
control
anim
inocul
nonrecombin
mva
salin
phosphatebuff
salin
pb
specif
induc
mvamerss
antibodi
merscov
confirm
absenc
detect
neutral
sar
coronaviru
sarscov
strain
fig
addit
merscovneutr
activ
serum
sampl
could
partli
block
preincub
protein
encompass
receptor
bind
domain
rbd
fig
f
last
observ
consist
fact
besid
rbd
part
spike
protein
abl
induc
neutral
antibodi
conclus
object
use
mva
vector
compat
clinic
evalu
express
mostli
nativ
antigen
induc
antibodi
would
neutral
merscov
gene
merscov
express
recombin
mva
produc
glycoprotein
migrat
molecular
mass
kda
glycosidas
treatment
remov
nlink
carbohydr
result
polypeptid
kda
close
correspond
molecular
mass
predict
gene
nucleotid
sequenc
subpopul
protein
appar
acquir
endo
h
resist
indic
traffick
golgi
apparatu
correl
observ
made
sarscov
protein
addit
obtain
evid
put
cleavag
fulllength
predict
recent
ha
tag
fuse
c
terminu
ha
enabl
us
detect
two
glycoprotein
subpopul
fulllength
kda
subdomain
kda
antiha
western
blot
analysi
fig
consid
furin
cleavag
site
spike
protein
betacoronavirus
gammacoronavirus
typic
activ
intracellular
furindepend
cleavag
review
see
merscov
virusneutr
titer
vnt
determin
day
primari
immun
day
second
immun
b
c
use
b
vero
cell
c
sera
obtain
second
boost
also
test
sarscov
vero
cell
serum
rabbit
immun
merscov
receptor
bind
domain
rbd
e
sera
mice
obtain
second
mva
boost
f
preincub
pb
rbd
sarscovderiv
control
protein
ctrl
gml
h
incub
merscov
follow
h
later
inocul
vero
cell
refer
server
indic
three
possibl
furin
cleavag
site
amino
acid
posit
merscov
data
shown
favor
put
cleavag
amino
acid
sinc
cleavag
would
produc
predict
subdomain
kda
nonglycosyl
protein
match
western
blot
data
fig
moreov
promin
endo
h
resist
subdomain
suggest
cleavag
occur
predominantli
passag
golgi
apparatu
sinc
biochem
character
mvaexpress
suggest
synthesi
matur
properli
fold
spike
antigen
investig
whether
mvamerss
would
elicit
virusneutr
antibodi
inde
mice
immun
mvamerss
via
intramuscular
rout
develop
circul
antibodi
neutral
merscov
infect
highli
permiss
tissu
cultur
interestingli
compar
result
previou
studi
elicit
neutral
antibodi
sarscov
mvamerss
induc
rel
high
level
antibodi
effici
block
merscov
infect
observ
may
explain
merscovspecif
differ
receptor
usag
entri
mechan
discuss
previous
previou
work
sarscov
show
sspecif
neutral
antibodi
correl
protect
capac
vaccin
variou
anim
model
review
see
refer
futur
studi
necessari
monitor
antibodydepend
enhanc
merscov
infect
previous
discuss
sarscov
felin
coronaviru
infect
furthermor
safeti
protect
capac
mvamerss
immun
test
anim
model
reproduc
merscov
infect
human
howev
current
absenc
suitabl
preclin
model
recommend
develop
mva
vaccin
deliv
merscov
